Suven Life Sciences, a clinical stage biopharmaceutical company discovering and developing novel medicines to treat Central Nervous System (CNS) disorders, has announced that the first subjects have been dosed in a Phase-1 clinical trial of SUVN-I6107 being conducted in USA under FDA acceptance of Investigational New Drug (IND) and issue of Study May Proceed letter.

SUVN-I6107 is the fifth internally discovered compound to advance into clinical trials and an exciting addition to Suven’s extensive, fully-owned pipeline of oral small molecules aimed at addressing large disease populations with significant unmet need in neuroscience.

The Phase-1 trial is a two-part randomized, double-blind, placebo-controlled, single and multiple ascending oral dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects (Clinicaltrials.gov Identifier NCT06705088).

Part-1 will be a single ascending dose (SAD) study, expected to enroll approximately 40 subjects across 5 cohorts. Part-2 will be a multiple ascending dose (MAD) study, expected to enroll approximately 24 subjects, randomized into 3 cohorts, each to receive SUVN-I6107 or placebo for 14 consecutive days.

The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs. Secondary objective is to determine the pharmacokinetic profile of SUVN-I6107 in healthy subjects. Exploratory endpoints will examine the effects of SUVN-I6107 on changes in quantitative electroencephalogram and event-related potential parameters, effect of food on pharmacokinetics of SUVN-I6107 and pharmacokinetic evaluation of SUVN-I6107 in cerebrospinal fluid.

SUVN-I6107 is a novel, potent, and selective muscarinic M1 positive allosteric modulator with minimal agonist-like activity. It exhibits no significant affinity for muscarinic subtypes M2 to M5. SUVN-I6107 demonstrates excellent pharmacokinetic properties and good brain penetration, achieving high cerebrospinal fluid concentrations in rats.

It has shown robust efficacy in animal models of cognition. Additionally, it has a wide margin of safety based on 28-day toxicity studies and anticipated efficacy. Suven Life Sciences owns the intellectual property rights for SUVN-I6107 in all major markets.